Predictive Biomarkers: a Paradigm Shift Towards Personalized Cancer Medicine

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2011 Aug 25

PMID 21862978

Citations 126

Authors

Nicholas B La Thangue

David J Kerr

Affiliations

Soon will be listed here.

Abstract

Advances in our understanding of the intricate molecular mechanisms for transformation of a normal cell to a cancer cell, and the aberrant control of complementary pathways, have presented a much more complex set of challenges for the diagnostic and therapeutic disciplines than originally appreciated. The oncology field has entered an era of personalized medicine where treatment selection for each cancer patient is becoming individualized or customized. This advance reflects the molecular and genetic composition of the tumors and progress in biomarker technology, which allow us to align the most appropriate treatment according to the patient's disease. There is a worldwide acceptance that advances in our ability to identify predictive biomarkers and provide them as companion diagnostics for stratifying and subgrouping patients represents the next leap forward in improving the quality of clinical care in oncology. As such, we are progressing from a population-based empirical 'one drug fits all' treatment model, to a focused personalized approach where rational companion diagnostic tests support the drug's clinical utility by identifying the most responsive patient subgroup.

Citing Articles

Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 Trial.

Dekker E, Janssen Q, van Dam J, Strijk G, Verkolf E, Kandala S Ann Surg Oncol. 2025; .

PMID: 39907876 DOI: 10.1245/s10434-025-16890-0.

Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives.

Molla G, Bitew M Biomedicines. 2025; 12(12.

PMID: 39767657 PMC: 11673561. DOI: 10.3390/biomedicines12122750.

Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials.

Mehta K, Hegde M, Girisa S, Vishwa R, AlQahtani M, Abbas M Mil Med Res. 2024; 11(1):76.

PMID: 39668367 PMC: 11636053. DOI: 10.1186/s40779-024-00582-z.

Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response.

Lee U, Szabova L, Collins V, Gordon M, Johnson K, Householder D Front Cell Dev Biol. 2024; 12:1462840.

PMID: 39512899 PMC: 11542432. DOI: 10.3389/fcell.2024.1462840.

Recent advances in minimally invasive biomarkers of OSCC: from generalized to personalized approach.

Suri S, Boora G, Kaur R, Chauhan A, Ghoshal S, Pal A Front Oral Health. 2024; 5:1426507.

PMID: 39157206 PMC: 11327221. DOI: 10.3389/froh.2024.1426507.

References

Heinrich M, Corless C, Demetri G, Blanke C, von Mehren M, Joensuu H . Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23):4342-9. DOI: 10.1200/JCO.2003.04.190. View

McConkey D . Proteasome and HDAC: who's zooming who?. Blood. 2010; 116(3):308-9. DOI: 10.1182/blood-2010-04-278507. View

Heinrich M . Imatinib treatment of metastatic GIST: don't stop (believing). Lancet Oncol. 2010; 11(10):910-1. DOI: 10.1016/S1470-2045(10)70225-4. View

Sasaki T, Rodig S, Chirieac L, Janne P . The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. 2010; 46(10):1773-80. PMC: 2888755. DOI: 10.1016/j.ejca.2010.04.002. View

Iorns E, Turner N, Elliott R, Syed N, Garrone O, Gasco M . Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell. 2008; 13(2):91-104. DOI: 10.1016/j.ccr.2008.01.001. View

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

Fine B, Amler L . Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. Clin Pharmacol Ther. 2009; 85(5):535-8. DOI: 10.1038/clpt.2009.9. View

Gridelli C, Bareschino M, Schettino C, Rossi A, Maione P, Ciardiello F . Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007; 12(7):840-9. DOI: 10.1634/theoncologist.12-7-840. View

Young R . Cancer clinical trials--a chronic but curable crisis. N Engl J Med. 2010; 363(4):306-9. DOI: 10.1056/NEJMp1005843. View

10.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

11.

August J . Market watch: emerging companion diagnostics for cancer drugs. Nat Rev Drug Discov. 2010; 9(5):351. DOI: 10.1038/nrd3173. View

12.

Papadopoulos N, Kinzler K, Vogelstein B . The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat Biotechnol. 2006; 24(8):985-95. DOI: 10.1038/nbt1234. View

13.

Karapetis C, Khambata-Ford S, Jonker D, OCallaghan C, Tu D, Tebbutt N . K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-65. DOI: 10.1056/NEJMoa0804385. View

14.

Segal N, Saltz L . Evolving treatment of advanced colon cancer. Annu Rev Med. 2009; 60:207-19. DOI: 10.1146/annurev.med.60.041807.132435. View

15.

Shankaran V, Obel J, Benson 3rd A . Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist. 2010; 15(2):157-67. PMC: 3227936. DOI: 10.1634/theoncologist.2009-0221. View

16.

Saltz L, Meropol N, Loehrer Sr P, Needle M, Kopit J, Mayer R . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22(7):1201-8. DOI: 10.1200/JCO.2004.10.182. View

17.

Ashworth A . A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008; 26(22):3785-90. DOI: 10.1200/JCO.2008.16.0812. View

18.

Wodarz D . Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. Proc Biol Sci. 2010; 277(1689):1875-80. PMC: 2871874. DOI: 10.1098/rspb.2009.2179. View

19.

Freemantle S, Spinella M, Dmitrovsky E . Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene. 2003; 22(47):7305-15. DOI: 10.1038/sj.onc.1206936. View

20.

Duffy M, Crown J . A personalized approach to cancer treatment: how biomarkers can help. Clin Chem. 2008; 54(11):1770-9. DOI: 10.1373/clinchem.2008.110056. View